Can Serum Fetuin-A be Used as a Marker for Cardiovascular Involvement in Psoriatic Patients?

Hanan M Saleh1, Aliaa S Sheha2, Nardeen N Eskander1

  • 1Dermatology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Insights

Serum Fetuin A levels are significantly lower in psoriasis patients and negatively correlate with coronary artery calcification, indicating its potential as a biomarker for cardiovascular risk in psoriasis.

Area of Science:

  • Cardiovascular Health
  • Dermatology
  • Biochemistry

Background:

  • Psoriasis is a systemic inflammatory disease linked to increased cardiovascular disease risk.
  • Fetuin A, a serum glycoprotein, may inhibit vascular calcification by forming calciprotein particles.
  • Subclinical atherosclerosis is a concern in psoriatic patients.

Purpose of the Study:

  • To measure serum Fetuin A levels in patients with psoriasis.
  • To correlate serum Fetuin A levels with cardiac events and risks using coronary calcium scoring.
  • To assess the relationship between Fetuin A, cardiovascular risk, and psoriasis severity.

Main Methods:

  • Serum Fetuin A levels and coronary calcium scores were measured in 24 psoriatic patients and 24 controls.
  • Psoriasis Area and Severity Index (PASI) scores were recorded.
  • Correlations between serum Fetuin A, calcium scores, and PASI were analyzed.

Main Results:

  • Psoriatic patients exhibited significantly lower serum Fetuin A levels compared to controls (P < .001).
  • A significant negative correlation was observed between coronary calcium score and serum Fetuin A levels (P < .001).
  • No significant correlation was found between serum Fetuin A levels and psoriasis severity.

Conclusions:

  • Reduced serum Fetuin A levels are associated with psoriasis.
  • Serum Fetuin A may serve as a valuable, accessible biomarker for detecting subclinical atherosclerosis in psoriatic individuals.
  • Fetuin A levels correlate with cardiovascular risk markers in psoriasis patients.
Abstract